Breaking News, Collaborations & Alliances

United Therapeutics, Corsair Enter License Agreement

United Therapeutics also made a minority equity investment in Corsair

United Therapeutics Corporation and Corsair Pharma have  entered into an exclusive license agreement for Corsair’s portfolio of patents covering treprostinil prodrugs.    Under the terms of the license agreement, United Therapeutics has been granted an exclusive license to Corsair’s intellectual property for the development of treprostinil prodrug formulations. Corsair will continue development of transdermal treprostinil prodrug formulations for PAH. Corsair received upfront...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters